CardioDx publishes PREDICT trial results CardioDx, a pioneer in the field of cardiovascular genomic diagnostics, today announced publication of outcomes from the Personalized Risk Evaluation and Diagnosis In the Coronary Tree trial in the Annals of Internal Medication, the journal of the American College of Physicians. Eric Topol, M information sur les médicaments .D., Director of the Scripps Translational Research Institute in La Jolla, Calif., may be the principal investigator for the trial. The critical query that we resolved – can the gene expression from white blood cells provide information about blockages of the coronary arteries? – was answered and validated in a go for cohort who underwent angiography also, said Dr.
today announced that the company has entered right into a distribution contract with Logista Pharma S.A. ‘We are very happy to possess entered into this agreement with Logista Pharma to distribute BRINAVESS to your Spanish customers,’ stated Karim Lalji, Cardiome's Chief Commercial Officer. Spain is an integral growth marketplace for BRINAVESS and our new romantic relationship with Logista Pharma can be one of many steps towards creating a successful brand in this country.’ The state-of-the-art processes developed by Logista Pharma will guarantee protected and timely fulfillment of BRINAVESS orders to all or any our hospital clients. Financial information on the agreement weren’t disclosed.. Cardiome enters into contract with Logista to distribute BRINAVESS within Spanish market Cardiome Pharma Corp.